- Home
- INBX vs TLSA Comparison
INBX vs TLSA Comparison
Compare INBX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- TLSA
- Stock Information
- Founded
- INBX 2010
- TLSA 2013
- Country
- INBX United States
- TLSA United Kingdom
- Employees
- INBX N/A
- TLSA N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- INBX Health Care
- TLSA Health Care
- Exchange
- INBX Nasdaq
- TLSA Nasdaq
- Market Cap
- INBX 178.5M
- TLSA 187.0M
- IPO Year
- INBX 2020
- TLSA 2000
- Fundamental
- Price
- INBX $21.60
- TLSA $2.38
- Analyst Decision
- INBX Hold
- TLSA
- Analyst Count
- INBX 1
- TLSA 0
- Target Price
- INBX N/A
- TLSA N/A
- AVG Volume (30 Days)
- INBX 148.3K
- TLSA 382.9K
- Earning Date
- INBX 08-12-2025
- TLSA 08-12-2025
- Dividend Yield
- INBX N/A
- TLSA N/A
- EPS Growth
- INBX N/A
- TLSA N/A
- EPS
- INBX 111.58
- TLSA N/A
- Revenue
- INBX $200,000.00
- TLSA N/A
- Revenue This Year
- INBX N/A
- TLSA N/A
- Revenue Next Year
- INBX N/A
- TLSA N/A
- P/E Ratio
- INBX $0.19
- TLSA N/A
- Revenue Growth
- INBX N/A
- TLSA N/A
- 52 Week Low
- INBX $10.80
- TLSA $0.63
- 52 Week High
- INBX $25.29
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- INBX 54.33
- TLSA 77.08
- Support Level
- INBX $20.84
- TLSA $1.62
- Resistance Level
- INBX $25.29
- TLSA $1.89
- Average True Range (ATR)
- INBX 1.84
- TLSA 0.18
- MACD
- INBX -0.41
- TLSA 0.09
- Stochastic Oscillator
- INBX 17.17
- TLSA 81.20
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.